eRapid electrochemical biomarker detection platform (IMAGE)

Wyss Institute for Biologically Inspired Engineering at Harvard

eRapid electrochemical biomarker detection platform

Caption

There is a vast need for point-of-care diagnostics that can rapidly detect multiple biomarkers, which is required to call out many diseases and disorders. The Wyss Institute’s eRapid electrochemical sensor technology able to do this has been licensed to Antisoma Therapeutics, a subsidiary of the Australian The iQ Group Global, to enable the development of new diagnostics for respiratory viral diseases, including COVID-19 and the Flu, allergic responses and anaphylaxis, as well as cancer.

Credit

Wyss Institute at Harvard University

Usage Restrictions

None

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.